Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
64.298,33
0,47%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Galmed Pharmaceuticals Ltd (GLMD) Galmed Pharmaceuticals Ltd (GLMD) Notizie

GLMD

Galmed Pharmaceuticals (GLMD)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GLMD
DataOraFonteTitoloSimboloCompagnia
04/04/202423:06PR Newswire (US)Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023NASDAQ:GLMDGalmed Pharmaceuticals Ltd
15/03/202414:00PR Newswire (US)Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
14/02/202420:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
30/11/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GLMDGalmed Pharmaceuticals Ltd
22/11/202322:48Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
20/11/202322:37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
20/11/202322:32PR Newswire (US)Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyNASDAQ:GLMDGalmed Pharmaceuticals Ltd
26/09/202314:30PR Newswire (US)Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
22/09/202322:05PR Newswire (US)Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:GLMDGalmed Pharmaceuticals Ltd
21/09/202313:30Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
21/07/202316:12Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:GLMDGalmed Pharmaceuticals Ltd
18/07/202315:23Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
14/07/202315:30PR Newswire (US)Galmed Pharmaceuticals Announces Pricing of $7 Million Public OfferingNASDAQ:GLMDGalmed Pharmaceuticals Ltd
13/07/202323:08Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
10/07/202314:00PR Newswire (US)Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSCNASDAQ:GLMDGalmed Pharmaceuticals Ltd
28/06/202314:41Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
28/06/202314:40Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:GLMDGalmed Pharmaceuticals Ltd
28/06/202314:38Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
16/06/202322:17Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
01/06/202314:14Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
01/06/202314:00PR Newswire (US)Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent DevelopmentsNASDAQ:GLMDGalmed Pharmaceuticals Ltd
09/05/202313:00PR Newswire (US)Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
29/03/202323:00PR Newswire (US)Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022NASDAQ:GLMDGalmed Pharmaceuticals Ltd
29/03/202322:32Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
08/02/202314:00PR Newswire (US)Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine SaltNASDAQ:GLMDGalmed Pharmaceuticals Ltd
04/01/202314:00PR Newswire (US)Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with AramcholNASDAQ:GLMDGalmed Pharmaceuticals Ltd
14/12/202223:00PR Newswire (US)Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price RequirementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
17/11/202212:25TipRanksH.C. Wainwright Remains a Hold on Galmed Pharmaceuticals (GLMD)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
08/08/202212:25TipRanksH.C. Wainwright Keeps Their Hold Rating on Galmed Pharmaceuticals (GLMD)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
04/08/202214:00PR Newswire (US)Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial ResultsNASDAQ:GLMDGalmed Pharmaceuticals Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GLMD

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
TIT
Telecom Italia
BIT
SPM
Saipem
BIT
SRG
Snam
BIT
TEN
Tenaris
BIT
TRN
Terna Trasmissione Elett...
BIT
IVG
Iveco Group NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network